Stacy M. Brown NNPA Newswire Senior National CorrespondentMay 27, 2021
With the most recent collaboration between Pfizer Rare Disease and the Black Press, the organizations embarked on a mission to educate and raise awareness to transthyretin amyloid cardiomyopathy – or ATTR-CM. “ATTR-CM is a rare, life-threatening, underrecognized, and underdiagnosed type of amyloidosis that affects the heart and it is associated with heart failure,” Dr. Kevin Williams, Pfizer’s chief medical officer, told the NNPA in a live interview.